<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04130100</url>
  </required_header>
  <id_info>
    <org_study_id>KT005SH002</org_study_id>
    <nct_id>NCT04130100</nct_id>
  </id_info>
  <brief_title>Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis</brief_title>
  <official_title>To Evaluate the Safety and Efficacy of Dental Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis Using Sodium Hyaluronate as a Parallel Control.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAR-T (Shanghai) Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CAR-T (Shanghai) Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy and safety of dental pulp mesenchymal stem cells in the
      treatment of primary mild to moderate knee osteoarthritis through a comparative study with
      sodium hyaluronate.

      20 participants will receive low dose of dental pulp mesenchymal stem cells, 20 participants
      will receive high dose and another 20 participants will receive sodium hyaluronate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 participants will receive to evaluate the clinical efficacy and safety of dental pulp
      mesenchymal stem cells in the treatment of primary mild to moderate knee osteoarthritis
      through a comparative study with sodium hyaluronate and verify the basis of dental pulp
      mesenchymal stem cells in the treatment of primary knee osteoarthritis, and to explore a more
      effective and safe clinical treatment of knee osteoarthritis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>low dose of dental pulp mesenchymal stem cells high dose of dental pulp mesenchymal stem cells Sodium hyaluronate</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kellgren and Lawrence's rating</measure>
    <time_frame>12 month</time_frame>
    <description>X-ray imaging was used to evaluate the degree of improvement in knee joint structure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WOMAC score</measure>
    <time_frame>12 month</time_frame>
    <description>WOMAC score decreased</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of femoral surface of knee joint on MRI</measure>
    <time_frame>12 month</time_frame>
    <description>Changes of volume of lateral femoral condylar, medial femoral condylar, lateral tibial condylar, medial tibial condylar and posterior patellar articular surfaces on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relaxation time of femoral surface of knee joint on MRI</measure>
    <time_frame>12 month</time_frame>
    <description>Changes of relaxation time (T1 condylar, T2 condylar, T2*) of lateral femoral condylar, medial femoral condylar, lateral tibial condylar, medial tibial condylar and posterior patellar articular surfaces on MRI</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Low Dose of Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving intraarticular injection of low dose of mesenchymal stem cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose of Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving intraarticular injection of high dose of mesenchymal stem cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Hyaluronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving intraarticular injection of Sodium Hyaluronate</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low Dose of Mesenchymal stem cell</intervention_name>
    <description>Mesenchymal stem cell injection</description>
    <arm_group_label>Low Dose of Mesenchymal stem cell</arm_group_label>
    <other_name>1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High Dose of Mesenchymal stem cell</intervention_name>
    <description>Mesenchymal stem cell injection</description>
    <arm_group_label>High Dose of Mesenchymal stem cell</arm_group_label>
    <other_name>2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate</intervention_name>
    <description>Sodium Hyaluronate injection</description>
    <arm_group_label>Sodium Hyaluronate</arm_group_label>
    <other_name>3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Complying with the diagnostic criteria for primary knee osteoarthritis revised by the
             American Rheumatological Association (1995), age 40-70 years, gender-free.

          2. For patients with mild to moderate knee arthritis, the WOMAC score of knee joint was
             less than 120.

          3. X-ray Kellgren-Lawrence was used to evaluate the grade I, II and III of
             osteoarthritis.

          4. Fertility patients should take effective contraceptive measures until the end of
             follow-up. Fertility women should exclude the possibility of early pregnancy, that is,
             HCG negative test in early pregnancy.

          5. Voluntary participation in this clinical study, can cooperate with doctors to carry
             out research, stop all medical measures for knee arthritis for more than 2 weeks, and
             sign the informed consent of patients.

        Exclusion Criteria:

        (1) Those with other diseases that may affect the knee joint, such as rheumatoid arthritis,
        ankylosing spondylitis, rheumatoid arthritis, gout and other rheumatic diseases, bone
        tumors, osteoporosis, bone tuberculosis or obvious history of acute trauma, resulting in
        meniscus injury, ligament rupture and vascular nerve injury; those with previous history of
        femur, tibial plateau, tibia and fibula fracture. The patients with gonarthritis, the
        patients with knee joint and surrounding skin infection were not cured.

        2) Patients who have undergone surgery and other factors affecting the efficacy of the
        treatment. Patients with severe deformities or even deformities of the knee joint, who need
        surgical treatment. Patients who have received knee joint irrigation or arthroscopic
        examination within one year.

        3) Patients with systemic cancer tendency or cancer and patients with systemic infection in
        active stage.

        4) Patients with severe heart, lung, liver, kidney, blood system, endocrine system and
        immune deficiency, or abnormal laboratory biochemical indicators, namely: hemoglobin (Hb) &lt;
        9 g/dL, white blood cell (WBC) &gt; 15 x 109/L, platelet (Pt) &lt; 100 x 109/L, glutamic oxalate
        transaminase (AST) and alanine aminotransferase (ALT) &gt; 1.5 times normal upper limit; serum
        creatinine &gt; 1.5 times normal upper limit.

        5) Physical history or clinical manifestations with bleeding tendency, including patients
        currently using anticoagulants.

        6) Patients with uncontrollable epileptic seizures, psychosis or Alzheimer's disease who
        are unable to complete the scale.

        7) Pregnant or lactating women, legal disabled patients (blind, deaf, dumb, mentally
        retarded, physically disabled), drug addiction and other adverse drug addiction.

        8) Patients with contraindications or allergies were examined and treated in this study.

        9) Those who have participated in other clinical studies within one month.

        10) Researchers consider it inappropriate for patients to participate in this clinical
        study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongbao Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongbao Zhao, Doctor</last_name>
    <phone>+86-18317079530</phone>
    <email>aolin_521@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhai hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangrong Song, Doctor</last_name>
      <phone>+86-13918384480</phone>
      <email>songguangrong@cart-sh.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

